Key facts
- Dxcover’s last known valuation is $37.8M (Jan 2025).
- It has raised $21.8M; the latest was Accelerator/Incubator ($6.2M) in Mar 2026.
- Notable investors include Innovate UK, European Innovation Council, Tech Nation Group, Scottish Enterprise, Mercia Ventures — 24 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 24 names
- ·Watchlist + deal alerts for Dxcover
- ·The full record, as it builds
Funding rounds
No funding rounds for Dxcover are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Dxcover
Developer of a liquid biopsy-based cancer diagnostics platform designed for the early detection of multiple cancer types. The company's platform combines infrared spectroscopy with multi-omic data analysis and machine learning algorithms to analyze blood samples, detect spectral signatures associated with disease, generate rapid diagnostic outputs without complex sample preparation, support high-throughput screening and triage of high-risk populations, integrate clinical data for improved predictive accuracy, and enable scalable deployment across healthcare settings, enabling clinicians, healthcare providers, and research institutions to identify cancers at earlier stages and improve diagnostic efficiency and patient outcomes.
- Sector
- Healthcare
- HQ
- Glasgow, United Kingdom
- Founded
- 2016
- Employees
- 31
- Website
- dxcover.com/
- Ownership
- Privately Held (backing)
Dxcover doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Dxcover shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Dxcover in its N-PORT filings yet. We sweep new filings monthly.